title: Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.
abstract: Breast cancer (BC) is a common malignancy affecting women, with increasing incidences of this disease in China every year. Recent studies have extensively investigated a single nucleotide polymorphism in the let-7 miRNA binding site of the 3'-untranslated region of KRAS mRNA. The aim of this study was to determine the genotype frequency of the KRAS rs712 polymorphism, and evaluate its effect on BC risk. This hospital-based case-control study comprised 228 patients with histologically confirmed BC and 251 healthy controls. The let-7a KRAS rs712 polymorphism was analyzed by polymerase chain reaction-restriction fragment length polymorphism. We observed no statistically significant association between BC risk and the let-7a KRAS rs712 polymorphism (GT vs GG, OR = 0.98, 95%CI = 0.66-1.46; TT vs GG, OR = 0.78, 95%CI = 0.28-2.21). However, the rs712 polymorphism was significantly associated with the N status of BC patients (GG vs GT/TT, OR = 0.52, 95%CI = 0.30- 0.92; G allele vs T allele, OR = 0.60, 95%CI = 0.37-0.97). We found no association between the let-7 rs712 polymorphism and BC risk. However, the let-7 rs712 G/T polymorphism was discovered to play a potential role in BC tumor metastasis; therefore, it may be employed as a new biomarker or therapy targeted towards resistant tumor metastasis.
authors.affiliation: Department of Laboratory Medicine, the People's Hospital of Leshan, Leshan, Sichuan, China.
authors.forename: X
authors.initials: X
authors.lastname: Huang
authors.affiliation: Department of Laboratory Medicine, the People's Hospital of Leshan, Leshan, Sichuan, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Laboratory Medicine, the People's Hospital of Leshan, Leshan, Sichuan, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Guo
authors.affiliation: Department of Laboratory Medicine, the People's Hospital of Leshan, Leshan, Sichuan, China.
authors.forename: Z L
authors.initials: ZL
authors.lastname: Cao
authors.affiliation: Department of Laboratory Medicine, the People's Hospital of Leshan, Leshan, Sichuan, China.
authors.forename: Z W
authors.initials: ZW
authors.lastname: Cui
authors.affiliation: Department of Cardiothoracic Surgery, the People's Hospital of Leshan, Leshan, Sichuan, China.
authors.forename: T C
authors.initials: TC
authors.lastname: Hu
authors.affiliation: Laboratory of Molecular and Translational Medicine, West China Institute of Women and Children's Health.
authors.forename: L B
authors.initials: LB
authors.lastname: Gao
mesh_terms: D020413:3' Untranslated Regions; D000328:Adult; D000368:Aged; D000483:Alleles; D001665:Binding Sites; D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D005787:Gene Frequency; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D012306:Risk
chemical_list: D020413:3' Untranslated Regions; C117307:KRAS protein, human; D035683:MicroRNAs; C487931:mirnlet7 microRNA, human; D016283:Proto-Oncogene Proteins p21(ras)